The Future of AgingPlay
Everybody’s getting older. Almost nobody wants to age.
Now there’s a huge industry in “anti-aging.” Eighty billion dollars a year in this country — spent on pills and guidance, anti-aging diets and exercise, hormones and more.
“Age management,” it’s being called. And it’s booming as boomers ... well, age. Testosterone sales are through the roof, with growth outstripping Viagra. For five thousand a year, we read, you can be kept tuned up like a race horse.
This hour, On Point: Age management. We’ll look at the real science and new horizons of aging.
You can join the conversation. Tell us what you think — here on this page, on Twitter, and on Facebook.
S. Jay Olshansky, professor at the School of Public Health at the University of Illinois - Chicago and author of "The Quest for Immortality: Science at the Frontiers of Aging."
Luigi Fontana, associate professor of medicine at Washington University in St. Louis and director of the division of nutrition and aging at the Italian National Institute of Health.
Nir Barzilai, director of the Institute for Aging Research at the Albert Einstein College of Medicine in New York City.
"Testosterone Is Sure Looking Virile" — BusinessWeek looks at surging sales of testosterone and reports that "despite legal setbacks and FDA delays, youth-crazed boomers are making it a billion-dollar industry."
"The Caloric Restriction Experiment" — The New York Times Magazine reports on the NIH-funded clinical trial called Calerie (Comprehensive Assessment of Long-Term Effects of Reducing Intake of Energy).
This program aired on November 5, 2009.